FDA approves ACTEMRA for children living with a rare form of arthritis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved ACTEMRA (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA). The medicine can be used in children two years of age and older with active disease. ACTEMRA can be given alone or in combination with methotrexate (MTX) in people with PJIA.
Roche to change Applied Science business structure
Roche today announced changes to the management and set-up of its life-science business. The Applied Science Business Area will be dissolved and its portfolio of products integrated within Roche's other Diagnostics Business Areas. This will streamline decision-making and enhance technology flow from research use to the clinical setting.
Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise